Table 3.
Choice of first-line therapy by comorbidity
|
N (%) of patients
|
||||||
|---|---|---|---|---|---|---|
| Antihypertensive | Diabetes (N=1258) | Angina (N=1538) | MI (N=725) | CHF (N=505) | Asthma (N=1776) | COPD (N=423) |
| Diuretic | 168 (13.4) | 281 (18.3) | 144 (19.9) | 188 (37.2) | 673 (37.9) | 159 (37.6) |
| Beta-blocker | 142 (11.3) | 372 (24.2) | 182 (25.1) | 27 (5.3) | 171 (9.6) | 23 (5.4) |
| CCB | 238 (18.9) | 410 (26.7) | 119 (16.4) | 74 (14.7) | 336 (18.9) | 90 (21.3) |
| AIIRA/ACE | 521 (41.4) | 142 (9.2) | 87 (12) | 75 (14.9) | 290 (16.3) | 59 (13.9) |
| Others | 23 (1.8) | 12 (0.8) | 5 (0.7) | 8 (1.6) | 22 (1.2) | 5 (1.2) |
| Combination | 166 (13.2) | 321 (20.9) | 188 (25.9) | 133 (26.3) | 284 (16.0) | 87 (20.6) |
MI=Myocardial infarction; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; CCB=calcium channel blocker; AIIRA=angiotensin II receptor antagonists; ACE=angiotensin converting enzyme